Shares of biotechnology firm Curis gained ground in today’s trading session, buoyed by an encouraging clinical data update. While market analysts have reaffirmed positive ratings, the company’s financial position continues to present significant challenges.
Clinical Data Shows Improvement in AML Study
The recent momentum follows the company’s presentation of updated results from its frontline acute myeloid leukemia (AML) trial this past Tuesday. The latest figures indicate progress: five out of eight patients, representing 62.5%, achieved a state with no detectable minimal residual disease. This marks an improvement from the four out of eight patients reported in the preliminary data released in July. The triple-combination therapy of emavusertib, venetoclax, and azacitidine maintained its established safety profile.
Beyond the AML program, Curis is advancing other clinical initiatives. These include a study for primary central nervous system lymphomas. Furthermore, the company is preparing for a planned Phase 2 trial in chronic lymphocytic leukemia (CLL), with initial patient recruitment anticipated for late 2025 or early 2026. The drug candidate emavusertib holds Orphan Drug designation for several indications, a status that can streamline regulatory pathways.
Should investors sell immediately? Or is it worth buying Curis?
Analyst Sentiment Remains Bullish
The positive clinical news prompted immediate reinforcement from the analyst community. Both JonesTrading and H.C. Wainwright reiterated their “Buy” recommendations for Curis equity. Their price targets, however, reflect a divergent assessment of risk associated with the promising yet unapproved therapy. JonesTrading established a target of $5.00, while H.C. Wainwright sees potential for the stock to reach $17.00.
Financial Resources Under Pressure
Despite the clinical advancements, Curis operates in a capital-intensive sector and faces a pressing need for additional funding. The company’s financial results underscore this tension. As of the end of September 2025, its cash and equivalents totaled $9.1 million. Management estimates these resources are sufficient to fund operations only into the first quarter of 2026. For the third quarter of 2025, Curis reported a net loss of $7.7 million against revenue of $3.2 million.
The equity’s future trajectory is expected to hinge on upcoming clinical milestones and financial developments. Initial data from the CLL study is projected for presentation at the American Society of Hematology meeting in December 2026. In the nearer term, the market’s continued reaction to the AML data and the company’s success in securing additional capital will be key drivers of share price movement.
Ad
Curis Stock: Buy or Sell?! New Curis Analysis from December 10 delivers the answer:
The latest Curis figures speak for themselves: Urgent action needed for Curis investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 10.
Curis: Buy or sell? Read more here...
